HALIFAX, Aug. 10 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today the introduction of new Multiplo(TM) rapid tests at the US Military's Advanced Technology Applications for Casualty Combat Care (ATACCC) Conference taking place this week in St. Pete's Beach, FL.

MedMira is launching several new combination rapid tests for infectious and tropical diseases, and sexually transmitted diseases at the ATACCC Conference. Specifically these new tests will be used to diagnose disease such as HIV, Hepatitis B and C, syphilis, malaria, and Dengue fever in various combinations. The expanded Multiplo(TM) line also includes monitoring capabilities for vaccination effectiveness, applicable in military pre-deployment screening, public health vaccination programs, and vaccine development trials.

Employing MedMira's distinctive and patented rapid flow-through technology, many of these new Multiplo(TM) tests will be the first of their kind in the diagnostics industry. The technology's unique advantages are multiple instant results on one test cartridge as well as the ease with which new test combinations can be geared up for full commercialization.

"Introducing our latest Multiplo(TM) diagnostic combinations at the ATACCC Conference is a good opportunity to clearly demonstrate the unique advantages and diversity of applications that our rapid diagnostic technology can offer to military medicine as well as civilian healthcare," said Hermes Chan, CEO, MedMira Inc. "There are some exceptional challenges in military medicine and we believe that our rapid diagnostics and technology can be very beneficial, bringing increased efficiency and improving patient outcomes."

The ATACCC brings together over 1,200 scientists and medical personnel and is the Department of Defense's (DOD) premier scientific meeting that focuses on the battlefield medical needs of warfighters and on recent advances in trauma surgery and medicine.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00013053E